The entire world fit inside a ballroom at Valparaiso University during the annual World Banquet sponsored by the Valparaiso ...

Global stocks mostly rose Thursday on easing trade tensions, with London and Frankfurt hitting record highs ahead of key US ...

US companies reported a mixed bag of earnings Thursday, with Ford falling after results and Hershey and Eli Lilly advancing ... a note from strategist David Song on Forex.com.

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before tomorrow’s bell. Given recent price action ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Love is in more than the air — it's also between the covers of dozens of books on display at IU's Lilly Library. Why it ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 116 trades. If we consider the specifics of each ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...